SNX29

Across TCGA pan-cancer cohorts, SNX29 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SNX29 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SNX29 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SNX29 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where SNX29 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	1.000	0.865	.002	62	view →
LUAD	DFS	Median	II,III,IV	0.690	0.292	.001	26	view →
PDAC	OS	Median	II,III,IV	0.281	0.435	.022	13	view →
HNSC	DFS	Tertile	III,IV	1.000	0.908	.038	1	view →
LSCC	DFS	Median	III,IV	0.868	1.000	.027	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SNX29–CCRCC (DFS)

Open the CCRCC breakdown →